HP
GILD icon

HealthInvest Partners’s Gilead Sciences GILD Stock Holding History

HealthInvest Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.83M Sell
46,142
-1,825
-4% -$240K 1.57% 28
2026
Q1 		$7.16M Sell
47,967
-2,829
-6% -$396K 2.31% 21
2025
Q4 		$6.23M Sell
50,796
-27,373
-35% -$3.33M 1.99% 23
2025
Q3 		$921K Buy
78,169
+5,004
+7% +$569K 3.42% 10
2025
Q2 		$8.11M Sell
73,165
-3,833
-5% -$408K 3.47% 11
2025
Q1 		$8.63M Buy
+76,998
New +$7.95M 3.81% 9
2024
Q2 		– Sell
-52,000
Closed -$3.81M – 43
2024
Q1 		$3.81M Sell
52,000
-46,974
-47% -$3.61M 2.32% 17
2023
Q4 		$8.02M Buy
+98,974
New +$7.7M 6.28% 3
2022
Q4 		$5.22M Sell
60,760
-44,240
-42% -$3.5M 10.07% 6
2022
Q3 		$6.48M Buy
105,000
+47,000
+81% +$2.96M 13.68% 3
2022
Q2 		$3.58M Sell
58,000
-40,000
-41% -$2.48M 8.26% 5
2022
Q1 		$5.83M Buy
+98,000
New +$6.26M 9.28% 6
2017
Q4 		$2.59M Sell
36,100
-40,500
-53% -$3.08M 5.46% 16
2017
Q3 		$6.21M Sell
76,600
-21,000
-22% -$1.61M 7.25% 12
2017
Q2 		$6.91M Sell
97,600
-19,400
-17% -$1.29M 8.61% 6
2017
Q1 		$7.95M Buy
117,000
+4,000
+4% +$281K 12.19% 3
2016
Q4 		$8.09M Buy
+113,000
New +$8.4M 7.46% 8
2016
Q1 		– Sell
-229,300
Closed -$23.2M – 19
2015
Q4 		$23.2M Sell
229,300
-20,000
-8% -$2.08M 10.92% 3
2015
Q3 		$24.5M Buy
249,300
+9,000
+4% +$1,000K 14.48% 1
2015
Q2 		$28.1M Buy
240,300
+117,000
+95% +$12.8M 14.37% 2
2015
Q1 		$12.1M Buy
123,300
+29,000
+31% +$2.94M 8.38% 6
2014
Q4 		$8.89M Buy
94,300
+5,000
+6% +$517K 7.35% 10
2014
Q3 		$9.51M Sell
89,300
-29,200
-25% -$2.86M 6.93% 7
2014
Q2 		$9.82M Buy
+118,500
New +$9.22M 5.53% 10

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HealthInvest Partners's GILD Position: Q2 2026 in Review

HealthInvest Partners reduced its Gilead Sciences (GILD) stake by 3.8% in Q2 2026, selling an estimated $240K and leaving 46,142 shares worth $5.83M. The position accounts for 1.57% of the portfolio, ranked #28.

HealthInvest Partners first reported a position in GILD in Q2 2014 and has held it in 24 quarters since. The position peaked at $28.1M in Q2 2015. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • HealthInvest Partners held 46,142 shares of Gilead Sciences worth $5.83M as of Q2 2026.
  • HealthInvest Partners sold 1,825 Gilead Sciences shares in Q2 2026, an estimated $240K.
  • Gilead Sciences made up 1.57% of HealthInvest Partners's portfolio in Q2 2026, its #28 holding.
  • HealthInvest Partners first reported a position in Gilead Sciences in Q2 2014 and has held it in 24 quarters since.
  • HealthInvest Partners's Gilead Sciences position peaked at $28.1M in Q2 2015.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on HealthInvest Partners's 13F filing for Q2 2026, filed 24 Jul 2026.